Ownership and insider activity for Quince Therapeutics, Inc. (QNCX): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Quince Therapeutics, Inc. (QNCX) operates as a biopharmaceutical firm dedicated to developing targeted treatments for debilitating and rare diseases. A cornerstone of their innovation is an extensive bone-targeting drug delivery platform, engineered to accurately transport diverse therapeutic agents, such as small molecules, peptides, and large molecules, directly to affected bone areas like fractures and disease sites.
Price
| Price | $27.17 |
| Market Cap | $8M |
| Exchange | NASDAQ |
| Country | US |
Balance Sheet (10y)
| Year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $7.3M | $24.9M | $51.2M | $66.8M | $69.7M | $44.6M | $20.8M | $6.2M | $5.8M |
| Short-term Investments | 0 | $46.8M | $48.6M | $67.0M | $37.1M | $45.6M | $54.3M | $34.6M | $11.9M |
| Receivables | 0 | 0 | 0 | 0 | $1.1M | 0 | $993000 | $882000 | $3.6M |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $7.5M | $72.6M | $106.1M | $137.9M | $111.7M | $93.7M | $77.4M | $44.0M | $22.9M |
| Property, Plant & Equipment | $122000 | $283000 | $1.3M | $1.1M | $1.4M | $684000 | $619000 | $813000 | $1.0M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | $17.6M | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | $5.9M | $63.7M | $60.0M | $67.8M |
| Total Assets | $7.7M | $72.9M | $124.4M | $189.5M | $133.2M | $103.9M | $180.2M | $114.5M | $93.5M |
| Accounts Payable | $517000 | $495000 | $3.1M | $3.6M | $4.9M | $570000 | $2.0M | $2.9M | $2.2M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | $64000 | 0 | $18.0M |
| Total Current Liabilities | $1.8M | $1.5M | $8.9M | $17.0M | $14.2M | $3.1M | $9.6M | $7.3M | $43.2M |
| Long-term Debt | $7.2M | 0 | 0 | 0 | 0 | 0 | $13.4M | $14.3M | $330000 |
| Total Liabilities | $28.0M | $1.5M | $8.9M | $17.2M | $14.6M | $3.3M | $95.1M | $84.3M | $129.2M |
| Retained Earnings | -$20.3M | -$32.8M | -$69.8M | -$146.7M | -$236.6M | -$288.3M | -$319.6M | -$376.5M | -$460.5M |
| Total Equity | -$20.3M | $71.4M | $115.5M | $172.3M | $118.6M | $100.6M | $85.1M | $30.1M | -$35.7M |
| Total Debt | $7.2M | 0 | 0 | $446000 | $1.2M | $453000 | $13.8M | $14.8M | $18.5M |
| Net Debt | -$172000 | -$71.7M | -$99.9M | -$133.4M | -$105.6M | -$89.7M | -$61.2M | -$26.0M | $719000 |
| Working Capital | $5.8M | $71.1M | $97.2M | $120.9M | $97.5M | $90.7M | $67.9M | $36.8M | -$20.3M |
Financial Health
| Debt / Equity | 0.00 |
| Current Ratio | 14.52 |
| Piotroski F-Score | 2 |
| Altman Z-Score | -8.15 |
Profitability
| Return on Equity | -413.28% |
| Return on Invested Capital | -104.64% |
| Return on Assets | -74.58% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ADVM · ALXO · ATYR · CAMP · CNTB · DTIL · GUTS
Explore sector: Healthcare · Biotechnology
More sections of QNCX: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks